Pfizer Inc.’s $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that the transaction may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.
Pfizer Inc. said on May 10 the company will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co., making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.
AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.
ReutersAxsome Therapeutics said on April 25 the company expects the U.S. health regulator to decline approval for the drug developer’s treatment of acute migraine over unresolved issues of its quality control processes, sending shares of Axsome down 20 percent.
AbbVie and Gedeon Richter signed an agreement to co-develop and commercialize a potential treatment for a range of neuropsychiatric diseases.
Drugmaker Biohaven Pharmaceutical said on December 6 the company’s intranasal spray to treat migraine showed rapid pain relief and met the main goals in a late-stage study.
The Food and Drug Administration cleared the way for Tonix Pharmaceuticals to begin a Phase II study of the company’s therapeutic candidate, which intends to prevent migraine headaches.
Amgen announced that the company’s Aimovig (erenumab-aooe) more than held the approved therapy’s ground against one of the most commonly prescribed migraine medications.
Biohaven Pharmaceutical Holding and Pfizer have partnered to market the Connecticut-based company’s migraine drug Nurtec ODT (rimegepant) outside of the United States once approved by global regulatory organizations.
Supernus Pharmaceuticals Inc. is acquiring Adamas Pharmaceuticals Inc. for about $400 million as the Rockville, Maryland-based company is expanding its portfolio of treatments for Parkinson’s disease and reducing reliance on the drugmaker’s top-selling epilepsy medicine, Trokendi XR.
